VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued on Wednesday. The firm set a “sell” rating on the stock.

A number of other research analysts also recently issued reports on the company. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research report on Wednesday, January 8th.

VolitionRx Trading Up 6.3 %

VNRX opened at $0.66 on Wednesday. The firm’s fifty day simple moving average is $0.65 and its 200 day simple moving average is $0.66. The stock has a market capitalization of $61.16 million, a P/E ratio of -1.83 and a beta of 1.20. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23.

Insider Activity

In other VolitionRx news, CEO Cameron John Reynolds acquired 139,811 shares of the business’s stock in a transaction on Monday, December 9th. The stock was purchased at an average price of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Guy Archibald Innes purchased 174,764 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was acquired at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the transaction, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. This represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 358,266 shares of company stock valued at $204,212. 12.80% of the stock is owned by insiders.

Institutional Trading of VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC increased its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is currently owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.